Key facts
- Notable investors include MassChallenge, MedTech Innovator, Hong Kong Science & Technology Parks, Shanghai Healthcare Capital, HKSTP Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Opharmic Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Opharmic Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Opharmic Technology
Manufacturer of ultrasound-mediated technologies intended and devices designed to provide non-invasive ocular drug delivery for a variety of eye diseases and conditions. The company's ultrasound technology is been precisely engineered to stimulate cellular transport activities and to modulate the barrier properties of the eye tissue or enhance drug uptake, enabling clients to replace needle injections and efficiently deliver drugs into the eye using the low-energy ultrasonic technology.
- Sector
- Healthcare
- HQ
- Hong Kong, Hong Kong
- Founded
- 2016
- Employees
- 4
- Website
- opharmic.com/
- Ownership
- Privately Held (backing)
Opharmic Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Opharmic Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Opharmic Technology in its N-PORT filings yet. We sweep new filings monthly.